Schrödinger Stock Is Trading Lower After Reporting Deeper Than Expected Q2 Loss

  • Schrödinger Inc (NASDAQ: SDGR) has reported Q2 revenues of $29.78 million, +29% Y/Y, slightly missing the consensus of $29.88 million.
  • Software revenue was $24.1 million, +15%. Drug discovery revenue was $5.7 million compared to $2.2 million a year ago, includes $3.3 million in collaboration revenue from Bristol Myers Squibb. 
  • The gross profit margin compressed from 58.8% to 40.2%, reflecting planned investment to drive and support the large-scale adoption of Schrödinger's platform.
  • Cash, cash equivalents, restricted cash, and marketable securities were $616.6 million.
  • Operating expenses increased to $42.3 million from $30.7 million in Q2 FY20, driven by costs required to scale its business and advance its internal drug discovery programs.
  • Schrödinger posted EPS loss of $(0.49) deeper than $(0.05) a year ago, missing the consensus loss of $(0.33).
  • FY21 Guidance: Schrödinger reaffirms revenue of $124 million - $142 million (midpoint $133 million lower than consensus of $138.8 million).
  • It expects software revenue of $102 million - $110 million and drug discovery sales of $22 million - $32 million.
  • The company expects operating expense growth of more than 42% and expects software segment gross margin to be lower than the 81% reported in 2020.
  • Price Action: SDGR shares are down 7.00% at $58.45 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!